CellRev has developed a scalable adherent cell processing platform for research and manufacturing. The company's patented manufacturing platform is an industry-first, facilitating faster, cheaper, and more sustainable production of cellular products. The breakthrough solution is founded on the ability to continuously grow, detach, and then collect adherent cells. CellRev's platform offers seamless translation from research to market with superior automation, control, and stability versus existing technologies. CellRev works with customers at any stage of bioprocess development and can support CDMOs to integrate our continuous process into broader production processes.

There are great environmental benefits in CellRev technology. We are developing a new bioreactor that can run as a continuous process, this has been recommended by the FDA for the highest quality but also because it dramatically reduces the resources needed to produce the final product. The amount of material and the energy that is required is much lower compared to the most standard batch processes.

For bioreactors used to generate cells sterility is very important so there’s a lot of single use plastic involved. With CellRev bioreactors’ continuous process the plastic will be used for six months or longer, reducing the amount of plastic and other waste. We are now focusing even more on the environmental impact of our technology – where initially, we were mostly focused on yield. CellRev can remove up to 98% single-use waste consumables fom the cell culture process.


Start Date









The Journey

“We joined the Innovate UK ICURe programme in early 2018 to address the challenges in the market and to start speaking to people to make sure what we were developing was really going to be useful to them – would they purchase it? I also wanted to make some connections and start to build relationships, it’s always more powerful to do that in person.”

“In 2019 the company raised pre-seed funds through a mixture of non-dilutive grants and direct investments, which really helped us push the company forwards. When we started, we had a proof of concept on the technology, but it’s different from having the real thing. We developed a working prototype and validated the technology, despite the challenges brought by the pandemic and having restricted access to the lab. In 2021 we raised £1m from a set of strategic investors to accelerate the development of our products and make a true innovative impact on the way cells are grown.”

“In January 2022 we hired Chris Green, a Chief Commercial Officer, now the CEO, which has been crucial in defining our strategy and working towards commercialisation. We raised an additional £1.75m in investment, and we have grown the team to 14 people. We undertook a full rebrand in 2022 and renamed to CellRev with a new logo and website.”

Martina Miotto, Co-Founder and CSO, CellRev

“In 2023 we demonstrated proof of principle with two functional bioreactor prototypes and have now generated first revenues. A partnership formed with Getinge, our corporate partner, will see our industry first continuous cell processing platform launch in March 2024. Our first reagent product, AggreGuard, is now on the market.”

Chris Green, CEO, CellRev

Contact Form

    Apr 2018

    Started on ICURe programme

    Dec 2018

    Company formed

    Jul 2019

    Spin out completed

    Jan 2021

    £1m investment raised

    Feb 2022

    £1.75m investment raised

    Jan 2023

    Entered pre-commercialisation phase

    Jun 2023

    Demonstrated proof of principle with two working bioreactors

    Oct 2023

    Raised our first invoice for a JDA with a large corporate partner

    Nov 2023

    Launched AggreGuard

    What companies had to say about the Innovate UK ICURe programme?

    Future Goals

    Having now validated the technology, CellRev need to show that it works in a prototype that can be used by potential customers. In 2023 it will commence external validations in collaboration with companies, which involves testing their cells in CellRev labs for compatibility with the technology. Once this had been successfully demonstrated, customers may purchase the CellRev technology.

    2024 will be the company’s first full year of trading with products now in the market or launching within the year. The company is in the process of finalising collaborations with customers to demonstrate the product use case with specific applications within the healthcare fields. CellRevs priority is now revenue growth and commercial traction. Our products are currently research grade, but our ambition is to see the technology used in a commercial setting within 2-3 years.